Spegra Tablet

Introduction

Spegra is a prescription medication that contains the active ingredients Dolutegravir, Emtricitabine, and Tenofovir Alafenamide. It is commonly prescribed for the treatment of HIV-1 infection in adults and pediatric patients weighing at least 35 kg.

Uses

Spegra is used to control the HIV-1 virus and prevent it from multiplying in the body. It is an antiretroviral medication that is primarily used as part of combination therapy for the treatment of HIV-1 infection in patients who have not previously received antiretroviral treatment or who have experienced treatment failure with other regimens.

Dosage and Administration

The dosage of Spegra may vary depending on individual factors, such as the patient’s age, weight, and medical history. Follow the instructions provided by your healthcare provider or the medication’s prescribing information. Typically, the recommended dosage for adults and pediatric patients weighing at least 35 kg is one tablet taken orally once daily, with or without food.

Mechanism of Action

Spegra contains three active ingredients: Dolutegravir, Emtricitabine, and Tenofovir Alafenamide. Dolutegravir belongs to a class of medications called integrase strand transfer inhibitors, which work by blocking the action of an enzyme called integrase. This enzyme is necessary for the replication of the HIV-1 virus. Emtricitabine and Tenofovir Alafenamide belong to a class of medications called nucleoside reverse transcriptase inhibitors, which work by inhibiting the reverse transcriptase enzyme, another key enzyme required for the replication of the virus.

Side Effects

Common side effects may include headache, nausea, diarrhea, and fatigue. Note that not all patients will experience these side effects, and they may vary in severity. If you experience any persistent or bothersome side effects. Consult your healthcare provider.

In some cases, Spegra may cause more serious side effects. These can include severe skin reactions, liver problems, and changes in kidney function. If you experience any signs of a severe skin reaction, such as a rash, blistering, or peeling of the skin, or signs of liver or kidney problems, such as yellowing of the skin or eyes, dark urine, or persistent abdominal pain, seek medical attention immediately.

Drug Interactions

Spegra may interact with other medications, including over-the-counter drugs, herbal supplements, and prescription medications. Inform your healthcare provider about all the medications you are currently taking or planning to take, including any changes or additions. Some medications may increase the risk of side effects or reduce the effectiveness of Spegra, while others may be affected by Spegra. Your healthcare provider can provide specific guidance regarding potential drug interactions.

Precautions

Before taking Spegra, inform your healthcare provider about any medical conditions you have, including liver or kidney problems. Disclose any allergies or sensitivities to medications. Spegra may not be suitable for everyone, and your healthcare provider will assess the potential risks and benefits before prescribing it to you.

Spegra should not be used in combination with certain medications, such as dofetilide or rifampin. Additionally, caution should be exercised when using Spegra with medications that can affect the kidneys or bone density, as well as medications that can increase the risk of bleeding.

Storage

Spegra should be stored at room temperature, away from moisture and heat. Keep the medication out of reach of children and pets. Do not use Spegra if it has expired or if the packaging is damaged.

Patient Tips

• Take Spegra exactly as prescribed by your healthcare provider. Do not change the dosage or stop taking the medication without consulting your healthcare provider.
• If you miss a dose, take it as soon as you remember. If it is almost time for your next dose, skip the missed dose and continue with your regular dosing schedule. Do not take a double dose to make up for a missed one.
• maintain regular follow-up appointments with your healthcare provider to monitor your response to treatment and to address any concerns or questions you may have.
• Spegra does not cure HIV-1 infection, but it helps to control the virus and improve your immune system. Continue practicing safe sex and taking other precautions to prevent the transmission of HIV-1 to others.
• If you have any questions or concerns about Spegra or your treatment plan, do not hesitate to contact your healthcare provider for further guidance.

Please note that this description, as well as the other content on our website is for educational purposes only. We do not provide medical advice. For specific medical advices, diagnoses and treatment options you should consult with your doctor.

References

• Dovato 50 mg/300 mg film-coated tablets (Health Professionals SmPC) Available at:
• Dolutegravir (Drugs.com) [Accessed 11 Jun. 2024] (online) Available at:
• abacavir 60 mg-dolutegravir 5 mg-lamivudine 30 mg tablet for oral susp (RX) [Accessed 3 Jun. 2024] (online) Available at:
• Dolutegravir (MedlinePlus) [Accessed 26 Jun. 2024] (online) Available at:
• Loosli T, Hossmann S, Ingle SM, Okhai H, Kusejko K, Mouton J, Bellecave P, van Sighem A, Stecher M, d’Arminio Monforte A, Gill MJ, Sabin CA, Maartens G, Günthard HF, Sterne JAC, Lessells R, Egger M, Kouyos RD. HIV-1 drug resistance in people on dolutegravir-based antiretroviral therapy: a collaborative cohort analysis. Lancet HIV. 2023 Nov;10(11):e733-e741. doi: 10.1016/S2352-3018(23)00228-X. Epub 2023 Oct 10. [Accessed 13 Jun. 2024] Available at: